News | March 20, 2008

Parachute Heart Pump Implanted in First U.S. Patient

March 21, 2008 – A central Ohio man has become the first person in the U.S., and only the 16th worldwide, to receive a heart implant called the CardioKinetix VPD Implant System designed to improve the heart’s pumping action and help manage congestive heart failure symptoms.

The procedure was performed at The Ohio State University Medical Center. The center is dedicated to heart failure and interventional research and is one of five academic medical centers participating in an FDA-approved safety and feasibility trial called U.S. PARACHUTE Trial. The device, CardioKinetix VPD Implant System, has FDA Investigational Exemption (IDE) approval for investigational use only and was developed by CardioKinetix Inc., Redwood City, CA.

Congestive heart failure occurs when a patient’s heart is not pumping blood efficiently, most often due to a weak heart muscle damaged by a prior heart attack. As part of a multicenter trial, the study device, which looks like a parachute turned inside out, is placed in the damaged portion of the pumping chamber of the heart and essentially partitions off the inefficient portion of the weakened heart chamber.

An advantage of the device is that it can be implanted via a small incision in the patient’s leg artery without the need for general anesthesia or open heart surgery, allowing for faster recovery time. Most patients, including the patient implanted at Ohio State, are discharged the day after the procedure.

“The concept of this device is to decrease the size of an abnormally enlarged heart with the hope of improving the patient’s symptoms such as shortness of breath, fatigue and swelling,” said Ernest Mazzaferri, Jr., M.D., an interventional cardiologist at Ohio State ’s Richard M. Ross Heart Hospital, who implanted the device March 11.

“This device has the potential to help many of these millions of heart failure patients,” said William T. Abraham, M.D., director of cardiovascular medicine at The Ohio State University Medical Center and national principal investigator for the trial.

The study is funded by CardioKinetix, Inc.

For more information: and

Related Content

Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD)| April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD)| March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD)| March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD)| March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Overlay Init